Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort

H. Worth (Fürth, Germany), R. Buhl (Mainz, Germany), P. Kardos (Frankfurt, Germany), V. Obermoser (Nürnberg, Germany), E. Gückel (Nürnberg, Germany), C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany)

Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Session: Clinical studies of COPD: combination inhalers and much more
Session type: E-poster session
Number: 989
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Worth (Fürth, Germany), R. Buhl (Mainz, Germany), P. Kardos (Frankfurt, Germany), V. Obermoser (Nürnberg, Germany), E. Gückel (Nürnberg, Germany), C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany). Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort. 989

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses
Source: International Congress 2017 – COPD management
Year: 2017


Compliance of pharmacotherapy with GOLD-guidelines: a longitudinal study in patients with COPD
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020


Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018



Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study
Source: International Congress 2018 – Eosinophils in airway disease
Year: 2018




Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD
Source: International Congress 2017 – COPD management
Year: 2017


QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018
Year: 2018



Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018


Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009

Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018


Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study
Source: Annual Congress 2010 - Management of airway disease
Year: 2010


Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021